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D908168 Differential Regulation of Ventricular ANPand
BNP synthesis in Compensated snd Overt Heart
Faiiure
R. Wlllenbrock, T. Langenickel, L Pagel, K. H6hnel, M. Scheuermann,
R. Dietz. Franz-Volhar&C//nic,HumboldtUnhwsi~,Berlin,Germany
Under physiological conditions the atrfal natriuretic peptide (ANP) is synthe-
sized in the atria while brain natriuretic peptide (BNP) is produced mainly in
theventriclea. Tha differential regulation of mRNA induction of ANP and BNP
is not well studied. The aim of this study was to analyse the induction of ven-
tricular mRNA for both peptides in two models of experimental hypettrophy
and heart failure. We induced compensated hypettrophy by a small infrarenal
aortocaval shunt and overi heari failura by a large ahunt in adult Wistar rats.
mRNA was measured by hybridisation with specific probes for ANP and
BNP in Northern Blot and Slot blot technique. All data were normalised to
GAPDH mRNA expression. In the compensated hypertrophy model ANP
plasma levels increased and significant cardiac hypertrophy developed in
all heart chambers. No hemodynamic alteration occurred. The overt heari
failure model was characterized by further elevated ANP plasma Ievela,
decreased cardiac contractility (dP/dt max), elevated enddiaatolic presaure,
increased lung weight and highar mortality. In compensated hypertrophy left
ventricular ANP-mRNA expression was induced four-foid (1.1 + 0.1 to 4.8
+ 0.7, arbitrary units, AU, p < 0.01) while BNP-mRNA expression was not
different from controls. In contrast, in overt heart failure, BNP-mRNA levels
increased significantly (0.7 + 0.1 to 2.9 + 0.4 AU, p c 0.01) whiie ventricular
ANP expression did not increase funher. Our data Indicate that the maximal
induction of ventricular ANP-mRNA wasalready achieved in compensated
hypertrophy while ventricular BNP-mRNA expression was only induced in
overt heart failure. BNP seems to be a more specific marker of severe heart
failure.
1908-169] DiffersrntiaiReguiation of CircuiatingAtrisi
Natriuretio Peptide and Brain Natriuretic Peptide
by Endogenous Endotheiin During the
Progression of Experimental Heart Faiiure
D.D. Borgeson, J.A. Grantham, E. Williamson, M.M. Radfield, A. Luchnar,
T.J. Opgenorth, J.C. Burnett, Jr. Cardiorena/ResearchLaboratow,Mayo
Clinic,RochestecMN,USA
While studias have established that mechanical stretch and humoral stim-
ulation enhances ANP and BNP syntheais andlor releaae, in vitro studies
suggest that ANP and BNP are differentially regulated and may be respon-
sive to stimulation by endothelin-1 (ET). We tested the hypothesis that ET
increasea circulating ANP and BNP during the progression of CHF, indepen-
dent of increases in cardiac filling pressures via the ET-A receptor subtype.
We determined circulating ANP and BNP during the progression of experi-
mental CHF produced by 21 days of rapid ventricular pacing in the presance
and abaenea of oral administration of an ET-A selective receptor antagonist
(A-127722, Abbott Pharmaceuticals, 5 mgikgbid PO).
ET pg/ml ANP, pg/ml BNP, pgrml RAP, mmHg PCWP mmHg
Untreated
Baseline 4.3 * 1,3 52& 16 35• 10 5.8 l 0.5 10.2 i 0.5
14 Days t4.4 +2aJ 1070 + 197a) 152+ 35’) 15.2 + 1.4a) 26,3+ 0.9aJ
21 Days 10.9 + 1.7a) 970+ 107aJ 256 + 438) 19.6 + OSa) 33,2 + 1.7aJ
Trested
Baseline 11,7+ 2.2b) 42+9 42+ 10 4.6 + 0.5 10.7+ 1.1
14 Days 17.4 l 2.s 276 +79b) 261 +62 15.9+ o.9al 25.6+ l.la)
21 Dsys 1S.9 + 6.5 346 + 93abJ 243 + 73a) 16.5 + 1.5aJ 28.3 + 1.5abJ
a) p <0.05 Vs Bsseline;b) p <0.05 Untrestedvs Trested
Thus chronic ET-A receptor antagonism in experimental CHF markedly
attenuated the increase in circulating ANP but not BNP in the absence of a
reduction in the increaae in cardiac filling presaures. These studias suggest
differential regulation of plasma ANP and BNP during the evolution of CHF
in which the increaae in circulating ANP, but not BNP is linked to the ET-A
receptor.
m908170 Long-term Effects of a High-Doae of TheEndotheiin Antagonist Boeentan in a Rat Modei of
Chronic Hesrt Faiiure
P.Mulder, M. Hogie, V. Richard, J.-P. Henry,J.-P. Clozel, C. Thuillez.
Depafimentof Pharmacology(VACOMED,lFRMPnQ23),RouenUniv.
M&. School,France
Haarl failure (HF) iacharacterizad by an increasa in plasma and tissua levels
of endothelin (ET). Blockade of its effects might be beneficial in HF. We
have previously shown that the ETA-ETs antagonist bosentan (Boa), at the
dose of 30 mg.kg-i day-i had no effect on survival or hemodynamics in a
rat model of HF [1], perhaps due to insufficient ET-receptor blockade. Thus,
we investigated the effects of a 6 month treatment with Bos, at the dose of
100 mg.kg-l day-l, on survival and ayatemic hemodynamics and mmpared
these effects to those of the ACE inhibitor cilazapril (Cil; 10 mg.kg-l day-l).
HF was inducad in rats by corona~ artery ligation and treatments were given
aa food admix, starting 7 days after ligation (n =52 par group). After 1, 3 and
6 months, systolic blood pressure (SBP) and heari rate (HR) were measured
in conscious rats. Table shows survival after 6 months, SBP and HR (*p c
0,05 vs HF; tp <0,05 VS 60s).
$uwivsl(%) SBP (mm Hg) HR (btsrmln)
1 3 6 1 3 6
HF 64 112* 1 lt7+ 2 119 + 1 398+8 40S + 8 425+5
HF + 60s 89* 109+2 IOe& 7* 112 + 1“ 374+7* 371 +8* 382+5’
HF + Cil 87* 80 h 2*t 80+ l’t 75+ l’t 393&6 369&7* 395&8*
Thus, Bos, at the dose of 100 mg.kg-’ day-i, improves sutvival to the
same extent as Cil. Although Bos reduces 56P less than Cil, both induce
similar, significant decreases in HR. These results demonstrate for the first
time that ETantagoniata improve survival in HF and suggest that these drugs
may be beneficial in this pathology.
[1] Mulder et al., JACC, 27,258, 1996.
908-171 Brain Natriuretic Peptide improves Diaetoiie
Function in the Normal and Faiiing Heart
K. Yamamoto, J.C. Bumatt, Jr., M.M. Redfield. MayoC//n/c,i%oheste~MN,
USA
Brain natriuretic peptide (EfNP) is the most potently natriuretic member of
the natriuratic peptide family, is a sensitive and specific marker of altered
LV structure and function and is being developed es a therapeutic agent for
heart failure (HF). As receptors for BNP are present on the myoeyte, wa
hypothesized that BNP may modulate ventricular function via activation of
ita aecond meaaenger, cGMP. To elucidate the effects of exogenous BNP
on LV function in the normal heart and to determine if the actions of BNP
are maintained in the presence of HF, an intraooronary infueion of BNP (25
rrg/k~min x 30 reins) was used to avoid systemic effects in 6 normal (N)
dogs and in 9dogs with chronic HF induced by rapid ventrfcularpacing. Heart
rate was controlled by atrial pacing during the infusion.
Resu/ts:(mean + SD, ‘ p <0.05 vs Control, Tau = the time constant of
LV relaxation, t = the time to the oneet of LV relaxation)
N HF
Control BNP Control BNP
LVSP (mmHg) 112 *s 111k5 95• 12 93* 11
LVEDP (mmHg) 6*6 4*4 10+6 10+6
Tsu (ins) 31 * s 24 &8* 77• 44 63 *43*
t (ins) 196+22 163* 27* 237 &21 233 %23
himitccrit (%) 43•2 44* 2 37*5 37*5
In both N and HF doga, BNP accelerated the rate of LV relaxation without
changes in LVEDP or hamatocrit to suggest deereasaa in venous return.
Peak + dP/dt did not incraase. In N dogs the time to onset of LV relaxation
was also shortened. We conclude that BNP has a specific effect to improve
LV relaxation which is unassociated with a positive inotropic effect and which
is maintained in HF. As impaired relaxation contribute to deterioration of
hemodynamica with exerciae in HF, the specific “lusitropic” action of BNP
represents a potentially important therapeutic action of this peptide.
[908-1721 DifferentiaiAtriai and VentricuiarExpreasionof
Myocardiai Brain-Natriuretic-Peptide During
Progressive Experiments Heart Faiiure
A. Luchner,T.L. Stevens, D.D. Borgeson, M.M. Redfield, C.-M. Wei,
J.G. Porter, J.C. Burnett, Jr. Carrfiorena/ResearchLaboratoryMayoClinic,
Rocheste&MN,USA
Although Brain-Natriuretic-Peptida (BNP) of myoesrdial origin is important in
cardiovascular and ranal function and as a marker of cardiac dysfunction, the
expression of BNP in atrial and ventricular rrryocardium in congestive heart
failure (CHF) remains controversial. We therefore determined left atrial (LA)
and left ventricular (LV) gene expression and tissue mncentration as well as
circulating BNP during the evolution of rapid ventricular pacing-induced CHF
in the dog (n = 15). Experimental Aeymptomatic LV Dyafunotion (ALVD, day
10 of pacing) was characterized by impaired LVfunction (EF31.8 & 3.0% vs.
normal 52.4 + 1.7, p c 0.03) but maintained arterial presaure (MAP 108 +
3 mmHg vs. normal 109 + 8, p = n.s.) and overt CHF (day 38) by further
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impairedLV function (EF 21.0 + 1.2%, p -=0.05 vs. ALVD and normal) and
decreased arterial pressure (MAP 97 + 7 mmHg, p <0.05 vs. normal). In
ALVD, BNP-mRNA (0.65 + 0.11 arbitra~unitsvs.normal0.23* 0.05,p -=
0.01)andtissuaBNP(90.7k 13.4pgrmgproteinvs.normal13.0+ 7.6,p <
0.01)weremarkedlyandexclusivelyincreasedinthe LAinassociationwith
an increasein circulating BNP (91.0 + 23.3 pg/ml vs. normal 15.2 + 2.2,
p = 0.05), while BNP-mRNA remained at the limit of detection in the LV. in
overI Cf-fF,LA BNP-mRNA increased further (0.99 + 0.09, p <0.02 vs. ALVD
and normal) with an additional increase in LV BNP-mRNA (1.23 + 0.29 vs.
normal 0.01 + 0.01, p < 0.01) and LV BNP (1.93 + 0.21 pg/mg protein vs.
normal 0.39 + 0.03, p < 0.01), all leading to an incraase in circulating BNP
(156.6 + 36.6 pg/ml, p <0.03 vs. normal). In the progression of CHF, atrfal
myocardium is the exclusive site for enhanced BNPsynthesisin ALVD.In
contrast,bothatrialandventricularBNPsynthesischaracterizeovertCHF.
Thesestudiesprovideimportantnewinsightintothetemporalregulationof
atrialandventrfcuiarBNPexpressionduringthe progressionof CHF.They
underscorea predominantendocrineroleforatrialmyocardiuminALVDand
a combinedrotaforatrialandventricularmyocardiuminovertCHF.
n909 Understanding the Consequences of Valvular
Heart Disease Using Noninvasive Imaging
Sunday,March 16, 1997, 5:00 p.m.-7:OOp.m.
Anaheim Convention Center, Hall E
Presentation Hour: 5:00 p.m.-7:OO p.m.
909-103 Identification of Abnormalities in Left Ventricular
Shape Despite Normal Volumea and Function in
Chronic Aortic Regurgitation By Quantitative
Shape Analysis - An Early Marker of Left
Ventricular Decompanaation?
M.Arsenault,H.Klenopf,M.Vannan,S.Smith,N.Pandian.Tufts-New
England Medical Center, Boston, Mass, USA
Ventricular geometry is known to be abnormal in dilated LV associated with
chronic aortic regurgitation (AR). Whether shape abnormalities precede LV
dilatation and dysfunction are not known. To address this ik.sue,we used
Fourier analysia and quantitation of regional curvature to assess ragionai
and global LV geometry in 17 pts with moderate to severe AR but normal LV
volumes and ejection fraction and 35 aged matched controls (N). By digitizing
LVendocardial borders (apical long-axis 2-Decho views), we derived Fourier
Power Index (FP,unitless), ameaeureof global shape, and regional curvature
(C, unitieee) values to quantify regional geomet~. Results: (*P <0.05 vs N,
mean k SEM) There were no differences in EF% (N:74 + 2 vs AR:78 + 2),
EDV (N:79 + 7 ml vaAR:64 + 7 ml) and ESV (N:21 + 2 ml vs AR:16 & 2 ml).
At end-diastole, although the aeptum exhibited decreased regional cuwature
in AR (C in N:8 + 0.6 vs AR:I1 + 0.7”), global LV shape did not differ from
normal. At end-systole, apiosl cuwature was decreased (C in N:27 + 1 vs
AR:32+2*)andwas asa0ciatedwith amoreglobularshape (P1in N:32+3VS
AR:20+2*). In conclusion, LV geometry can beaffectad despite normal size
and preserved e@ctionfraction. Fourier power index and regional cuwature
analysis canbe usedto detectthesesubtle but quantifiable changes in LV
shape in patienta with AR.
m909104 Alteration in Left Ventricular Geometry in
Patienta with Rheumatic Mitral Stenbsis: a
Quantitative Analysis of Regional and Global
Shape
M.Areenault,N.Maeani,S. Mittel,A. Kanojia,A. Omar,R.Kaeliwai,
T.-L.Hsu,N.Trehan,N.Pandian.Turk-rVew ErrgLsrrdhfadics/Cerrtefi
Boston, Mass, USA, Escorts Health Center& Research Institute, New
Delhi, India
Afthoughthepredominantpathophysiologicaiettectofrheumaticmitraisteno-
sis (MS) is obstructionto left ventricular(LV) inflow,LV functionis also
frequentlyaffected.We postulatedthat abnormalfillingcharacteristics,my-
ccatdialfibrosisandalteredinteractionswiththe RVmayresultin changes
in LVgeometry.Aecordingiy, we studied 16 patients with MS and 32 nor-
mals using quantitative measures of global (Fourier Power analysis, FP) and
regional(QuantitativeRegionalCuwatureanalysis,C)shape.Enddiastolic
and end-systolicLV endooarcfialborders,from apicsl longaxis (lAX) and
fourchamber(4C)echooerdiogrems,weredigitizedandanalyzed.Results:
there were no differencesin C betweenMS and normalpatientaat end-
diaatoleorend-syatole.However,in MS,FPanalysisrevealeda reductionof
thaelongationcomccmentof giobelLVahape,withanincreaseinpolygonal
components (indicated by a reduction in FP3 of 0.27 + 0.05 vs 0,36 + 0.07
in diastole and 0.34 + 0,1 vs 0.46 + 0,1 in systole, both p e 0.05). Further-
more, at end systole in both 4C and LAX views, there was an increase in LV
sphericity (indicated by an increase in FP index of 15.5 + 8.6 vs 32.0 + 16.0
in IAX and 17.1 + 9.0 vs 30.3 + 11.8, both p < 0.05). We conciude that LV
geometry is altered in patients with MS. These obsewations form the basis
of studies to determine the pathophysiological and prognostic importance of
altered LV geometry in rheumatic mitral valve disease.
I909-105] lnfluenCeofLeft AtrialSizeon Pulmonary Venous
Flow in Pstients With Moderate to Severe Mitral
Regurgitation
M. Nanna, J. Wu, M.-H. Lee. Montefiore Medical Center/AECOM, Bx, NY
USA
Systoiic pulmonary venous flow velocity blunting or reversal in mitrai re-
gurgitation reflects the complex interaction of physical and hemodynamic
parameters related to left atrium, left ventricle and pulmonary veins as well
as regurgitant volume. We hypothesized that in patients with moderate to
severe mitral insufficiency, systolic pulmonary venous velocity is also influ-
enced by left atrial size, Eighty threa patients with moderate to severe mitral
regurgitation, proven by angiography and Color Doppler, undergoing TEE
examination were studied. Pulmonary venous flow velocity in systole and
dieetole were obtained from at least two separate pulmonary veins and peak
syatolicto diastolic flow velocity ratio (S/D) was measured. Left atrial volumes
were measured using the prolate allipsoid formula. Patients were divided into
Gr. I (IAvolume <100 cm3) and Gr. II (LA volume >100 cm3). Resu/ts:LVEF
was similar in Gr. I and il (58 + 5% and 80 + 4, respectively; p = NS) the
severity of MR (scale 1-4) was also similar in the two groups (3.7 + 0.2 va
3.8 + 0.2p= NS). In Gr. 1,49% of the pts were in atrial fibrillation vs 56% in
Gr. II (p= NS). In Gr. I a significantly lower S/D ratio was noted compared to
Gr. II (0.37+ 0.04 vs. 0.57+ 0.07p < 0.05).
Conclusions: A smaller left atrium magnifiaa, whereas a iarger left atrium
attenuates the decrease in systoiic pulmonary vein ffow velocity found in
presence of moderata to severe mitral insufficiency. LA size should be taken
into account when using systolic pulmonary venous flow abnormalities aa a
marker of mitral regurgitation severity.
~909-1061 DOSSMitral RegUrgitStiOnAffeCtthe Validity of the
Interpretation of Disetolic Filling Parameters? A
Quantitative Echocardiographic Study
N.K. Tahirkheii, M.E. Sarano. Mayo C/inic, Rochastec MN, USA
Doppler Echocerdiography allows the assessment of left ventricular diastolic
filling parameters (LVDFP). Restrictive filling patfern (RFP) is characterised
byshortdeceleration time <150 (DT) andhighE/A(earlydiastolicfilIing/atrtal
filling)ratio>2. Restrictivepatternis an independentpredictorof outcome.
Animaldatasuggeststhat mitral regurgitation (MR)mayalterthe (LVDFP),
creatingtheappearanceof a rastrictivapattern.Thishaanever baen quan-
titatively studied in humans. Weprospectively atudied 327 patients with MR.
Those with atrial fibrillation or fused earfy (E)and atrial fiiling (A) were ex-
cluded.Meanagewas63.9andmeanejectionfraction(EF)waa55’Yo.
RFP NO-RFP P
N 37 290
EDVI(mi/m2) 150+45 119*39 0.0003
EF(%) 33.6+ 15 5S& 16 0.0001
RV(ml) 36.2& 2S 55.9l 44 0.0003
RF(%) 37.6+ 16 3S.6k le 0.714s
EDVI(enddiaatolicvolumeindex),RV(Dopplerregurgitationvolume),RF(Doppleregur-
gitantfraction).
Correlationanalysisrevealedthat DTandA are notsignificantlyrelated
to RF(pvalue0.662and0.233,respectively),whileE (pvalue0.0001)and
E/A(pvalue0.04)are significantlyrelated.Wethareforeconcludethat MR
1)mcdifiesLVDFPbyincreasingEandE/A,2) doesnotalterDTorAand 3)
doesnot induceRFP.
1909-107 ]PrevalenceandM eChaniamOfisCherniCM Rral
Regurgitation by Echocardiography
J.C.Field,C.A.Roldan,M.H.Crawford.The University of New Mexico,
Albuquerque, NM, USA
Mitral regurgitation (MR) associated with coronary artery disease (CAD)
is of prognosticimportance.However,limited data is availableabout its
prevalence,distributionand mechanism.Therefore,wa reviewedfrom our
echoosrdiographylaboratorydatabase898echocardiogramsmnsistentwith
